School of Basic Medicine, Health Science Center, Yangtze University, Jingzhou, 434023, China.
Jingzhou Hospital of Traditional Chinese Medicine, Jingzhou, 434000, China; The Third Clinical Medical College of Yangtze University, Jingzhou, 434000, China.
Cancer Lett. 2024 Oct 1;601:217184. doi: 10.1016/j.canlet.2024.217184. Epub 2024 Aug 12.
Prostate cancer (PCa) is the second most prevalent cancer in men worldwide, presenting a significant global public health challenge that necessitates early detection and personalized treatment. Recently, non-invasive liquid biopsy methods have emerged as promising tools to provide insights into the genetic landscape of PCa and monitor disease progression, aiding decision-making at all stages. Research efforts have concentrated on identifying liquid biopsy biomarkers to improve PCa diagnosis, prognosis, and treatment prediction. This article reviews recent research advances over the last five years utilizing extracellular vesicles (EVs) as a natural biomarker library for PCa, and discusses the clinical translation of EV biomarkers, including ongoing trials and key implementation challenges. The findings underscore the transformative role of liquid biopsy, particularly EV-based biomarkers, in revolutionizing PCa diagnosis, prediction, and treatment.
前列腺癌（PCa）是全球男性第二大常见癌症，对全球公共健康构成重大挑战，需要早期发现和个性化治疗。最近，非侵入性的液体活检方法已成为探索 PCa 遗传特征和监测疾病进展的有前途的工具，有助于在各个阶段做出决策。研究工作集中在寻找液体活检生物标志物，以改善 PCa 的诊断、预后和治疗预测。本文综述了过去五年中利用细胞外囊泡（EVs）作为 PCa 天然生物标志物库的最新研究进展，并讨论了 EV 生物标志物的临床转化，包括正在进行的试验和关键实施挑战。这些发现强调了液体活检，特别是基于 EV 的生物标志物在彻底改变 PCa 诊断、预测和治疗方面的变革作用。
